We set our target to reduce in absolute value our waste generation by 18% by 2030, compared with our 2019 base year. We manage to recover a large majority of our waste generated on site worldwide, predominantly through recovery of waste as a fuel to generate energy and recovery and regeneration of solvents.
Our waste mapping reinforces the need to focus on reducing the amount of fresh raw materials used in chemical production. We are therefore paying close attention to the environmental impacts of chemical manufacturing, and more specifically, working on the eco-design of our medicine production processes.
To evaluate our efforts in this area, UCB adopted the Process Mass Intensity (PMI) metric developed by the American Chemical Society’s (ACS) Green Chemical Institute (GCI). This method allows to monitor the quantity of raw materials (kg) needed to manufacture 1 kg of active pharmaceutical ingredient – the smaller it is, the less waste is generated.
For every new synthetic molecule, we follow three best practices to minimize waste generation: